CHAARM is an acronym for Combined Highly Active Anti-Retroviral Microbicides.
In other words, the purpose of the project is to develop combinations of new and existing microbicides that will be designed to be specifically targeted agents, which can be applied topically to reduce transmission of HIV during sexual intercourse.
It is a large scale collaborative project co-funded by the European Union under the 7th Framework Programme (FP7) for Research and Technological Development.
Project partners would like to welcome you to this website which aims to highlight who is CHAARM, their research objectives, and why the work that will be carried out in the project is essential to the ongoing mission to prevent HIV infection.
CHAARM brings together some of the top researchers and scientists from around the world. It is a consortium of 31 partners from academic institutions, research organizations, small and medium enterprises, and larger industries, representing 9 different countries in Europe including Ukraine, as well as South Africa and the U.S.A. Each research partner has a different focus and unique role in the project while playing an integral part in the success of CHAARM.
The project coordinator is King’s College London based in the UK who has participated in other European Commission microbicide research initiatives before, such as EMPRO. The CHAARM project will run for 5 years beginning January 2010 and ending December 2014.
CHAARM has a budget of 17 million euros with an EC contribution of 12 million euros.
CHAARM aims to:
To further develop new and promising microbicides against HIV-1.
The researchers will investigate combinations of highly active anti-retroviral agents which may be effective as microbicides.
Depending on which show the most promise, they will move the best microbicide candidates towards clinical trials.